Young Pectus Excavatum Patients and Genetic Defects

Sponsor
Erasmus Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT05443113
Collaborator
(none)
18
1
13
1.4

Study Details

Study Description

Brief Summary

In most pectus excavatum (PE) patients an underlying genetic defect is not found with molecular analysis, as a direct genetic link with PE has yet to be found and because potential underlying genetic disorders are quite rare. Only one-fifth of all PE cases are identified in the first decade of life and thus of congenital origin making younger PE patients a unique patient group. Therefore, the research question is; is early-onset pectus excavatum (PE) more likely to be part of a genetic defect than PE which became apparent during puberty or adolescence?

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Genetic analysis

Detailed Description

Importance: In most pectus excavatum (PE) patients an underlying genetic defect is not found with molecular analysis, as a direct genetic link with PE has yet to be found and because potential underlying genetic disorders are quite rare. Only one-fifth of all PE cases are identified in the first decade of life and thus of congenital origin making younger PE patients a unique patient group.

Objective: the investigators hypothesize that early-onset PE is more likely to be part of a genetic defect than PE which became apparent during puberty or adolescence.

Design: Cohort study Setting: Single center Participants: All pediatric PE patients aged younger than 11 years upon first visit of the outpatient clinic of the department of pediatric surgery at the Sophia Children's Hospital - Erasmus Medical Center between 2014 and 2020 were identified and informed consent was obtained for inclusion. Two clinical geneticists performed the anamnesis and physical examination. Molecular analysis was performed based on the differential diagnosis. All young PE patients which have been referred for genetic counseling already, were analyzed retrospectively.

Main Outcome: incidence of genetic defects

Study Design

Study Type:
Observational
Actual Enrollment :
18 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Early Onset Pectus Excavatum is More Likely to be Part of a Genetic Defect
Actual Study Start Date :
Sep 1, 2019
Actual Primary Completion Date :
Oct 1, 2020
Actual Study Completion Date :
Oct 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Children (<11 years) with pectus excavatum

All pediatric PE patients aged younger than 11 years upon first visit of our outpatient clinic

Diagnostic Test: Genetic analysis
Genetic analysis by geneticists

Outcome Measures

Primary Outcome Measures

  1. Incidence of genetic variations [Baseline]

    Incidence of genetic variations in children (<11 years) with pectus excavatum

Secondary Outcome Measures

  1. Evaluation checklist referral of a patient with pectus excavatum for genetic counseling [Through study completion, an average of 1 year]

    Evaluation and validation of checklist referral of a patient with pectus excavatum for genetic counseling

Eligibility Criteria

Criteria

Ages Eligible for Study:
0 Years to 11 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with pectus excavatum aged younger than 11 years upon first visit of our outpatient clinic
Exclusion Criteria:
  • None

Contacts and Locations

Locations

Site City State Country Postal Code
1 Erasmus Medical Center Rotterdam Zuid-Holland Netherlands 3015CE

Sponsors and Collaborators

  • Erasmus Medical Center

Investigators

  • Principal Investigator: RenĂ© M Wijnen, Erasmus Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ryan Billar, Principal investigator, Erasmus Medical Center
ClinicalTrials.gov Identifier:
NCT05443113
Other Study ID Numbers:
  • MEC-2012-387
First Posted:
Jul 5, 2022
Last Update Posted:
Jul 5, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ryan Billar, Principal investigator, Erasmus Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 5, 2022